Walleye Capital
FRTX

Walleye Capital’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

Walleye Capital’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$140K Buy
+324
New +$137K 0.07% 245

Other funds holding FRTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Walleye Capital's FRTX Position: Q3 2018 in Review

Walleye Capital opened a new position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q3 2018: 324 shares worth $140K. The stake represents 0.07% of the portfolio and ranks #245 among its holdings.

32 funds tracked by Wall St. Rank hold FRTX as of Q3 2018.

  • Walleye Capital held 324 shares of Fresh Tracks Therapeutics, Inc. Common Stock worth $140K as of Q3 2018.
  • Fresh Tracks Therapeutics, Inc. Common Stock was a new Walleye Capital position in Q3 2018.
  • Fresh Tracks Therapeutics, Inc. Common Stock made up 0.07% of Walleye Capital's portfolio in Q3 2018, its #245 holding.
  • 32 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Walleye Capital's 13F filing for Q3 2018, filed 14 Nov 2018.